Biotechnology News TYGACIL Search

BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login

Search Results

Documents 1-3 out of 3 found

Current Search: tygacil: 3

Wyeth Q2 profit declines on charges; Adj. EPS beats consensus; lifts FY08 EPS outlook - Update
(RTTNews) - Wednesday morning, drug maker Wyeth (WYE | Quote | Chart | News | PowerRating) reported a more than 6% decline in its profit for the second quarter on charges related to severance and other employee-related costs due to a...

TradingMarkets: Jul 23 2008 3:07PM
Matching: tygacil

Find similar documents

Rib-X initiates Phase II skin infection trial
This Phase II double-blind study (study RX-3341-201) will evaluate the safety and efficacy of RX-3341 at two different doses administered intravenously to hospitalized complicated skin and skin structure infections (cSSSI) patients every 12...

Pharmaceutical Business Review: Jul 17 2008 1:03PM
Matching: tygacil

Find similar documents

Wyeth's tigecycline gets US FDA approvable letter
Wyeth Pharmaceuticals, a division of Wyeth, announced that the US Food and Drug Administration (FDA) has issued an approvable letter for the first-in-class antibiotic Tygacil (tigecycline) for the treatment of adult patients with...

PharmaBiz: Jun 2 2008 6:54AM
Matching: tygacil

Find similar documents

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright � 1997-2008 - BioPortfolio Limited.